Elsevier

American Heart Journal

Volume 166, Issue 4, October 2013, Pages 622-628.e1
American Heart Journal

Curriculum in Cardiology
Rheumatoid arthritis and cardiovascular disease

https://doi.org/10.1016/j.ahj.2013.07.010Get rights and content

Background

Rheumatic disease and heart disease share common underpinnings involving inflammation. The high levels of inflammation that characterize rheumatic diseases provide a “natural experiment” to help elucidate the mechanisms by which inflammation accelerates heart disease. Rheumatoid arthritis (RA) is the most common of the rheumatic diseases and has the best studied relationships with heart disease.

Methods

A review of current literature on heart disease and RA was conducted.

Results

Patients with RA have an increased risk of developing heart disease that is not fully explained by traditional cardiovascular risk factors. Therapies used to treat RA may also affect the development of heart disease; by suppressing inflammation, they may also reduce the risk of heart disease. However, their other effects, as in the case of steroids, may increase heart disease risk.

Conclusions

Investigations of the innate and adaptive immune responses occurring in RA may delineate novel mechanisms in the pathogenesis of heart disease and help identify novel therapeutic targets for the prevention and treatment of heart disease.

Section snippets

Epidemiology of heart disease in RA

Patients with RA have a 1.5- to 2.0-fold increased risk of developing coronary artery disease (CAD) compared with the general population,1, 2 similar in magnitude to the risk imparted by diabetes mellitus.3 This increased CAD risk is evident even before the clinical recognition of RA: at diagnosis, individuals with RA were more than 3 times as likely to have had a prior myocardial infarction (MI) than subjects without RA.2 An expert committee of the European League Against Rheumatism has

Cardiovascular risk factor profile in RA

Patients with RA tend to have a different profile of cardiac risk factors, including a higher frequency of smoking and an altered lipid profile, compared with the general population. The lipid profile in RA is characterized by suppression of total and low-density lipoprotein (LDL) cholesterol levels during periods of high-grade inflammation, with a proportionately greater suppression of high-density lipoprotein (HDL) levels, yielding an unfavorable ratio of total to HDL cholesterol. Lipid

Heart disease management/outcome in RA

Patients with RA are typically managed by several physicians, and coordination of care may be suboptimal. Smoking cessation and control of standard risk factors are all indicated in patients with RA but may be underused because of the understandable focus on management of RA itself. Despite the well-understood benefits of exercise on general and CV health, most patients with RA do not pursue a regular exercise program.22, 23 Both aerobic exercise training and resistance exercise training for

Effect of RA therapies on CV risk in RA

Rheumatoid arthritis therapies target inflammation, a CV risk factor that is also important in patients without rheumatic disease. Understanding how these therapies also modify CV risk in RA may provide insight into the inflammatory component of CV risk for all patients.

Glucocorticoids have been widely used in RA to acutely control pain and inflammation associated with RA flares. However, the beneficial anti-inflammatory effects of glucocorticoids, which can improve mobility, are also

Effect of heart disease therapies in patients with RA

There have been relatively few patients with rheumatic diseases enrolled in major clinical trials of primary or secondary prevention. Although commonly used CV therapies are presumed to be effective in patients with RA, there is little direct evidence of their efficacy.

Statins (hydroxymethylglutaryl CoA reductase inhibitors) appear to reduce vascular inflammation and have been tested for efficacy in the treatment of RA. Atorvastatin treatment resulted in a small reduction in RA disease activity

Mechanisms of RA pertinent to CV disease

Emerging evidence suggests that T lymphocytes play a crucial pathogenic role in both RA and heart disease.58, 59 The major risk gene for RA, HLA-DRB1, predisposes to disease by promoting the selection and survival of autoreactive CD4+ T cells. HLA-DRB1 alleles are also associated with increased risk of MI and various forms of non–RA-associated heart disease.60, 61 As in heart disease, T cells isolated from the joints of patients with RA have enhanced production of interferon-γ and

Conclusion

Heart disease remains a major problem for patients with RA. Systemic inflammation plays a major role, through direct and indirect effects on the vasculature (Figure 2). More research is needed to delineate the disease mechanisms and to develop and evaluate risk assessment tools, biomarkers, prevention strategies, and treatments that are specific to RA. The CV risk in patients with RA is not well recognized by practicing physicians, and better recognition and control of traditional risk factors

Disclosures

No extramural funding was used to support this work. The authors are solely responsible for the design and conduct of this work, the drafting and editing of the manuscript, and its final contents.

References (79)

  • J.S. Smolen et al.

    Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial

    Lancet

    (2008)
  • P.M. Ridker et al.

    Interleukin-1beta inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)

    Am Heart J

    (2011)
  • D.H. Solomon et al.

    Patterns of cardiovascular risk in rheumatoid arthritis

    Ann Rheum Dis

    (2006)
  • H. Maradit-Kremers et al.

    Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study

    Arthritis Rheum

    (2005)
  • M.J. Peters et al.

    Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study

    Arthritis Rheum

    (2009)
  • M.J. Peters et al.

    EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis

    Ann Rheum Dis

    (2010)
  • P.J. Nicola et al.

    The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years

    Arthritis Rheum

    (2005)
  • J.M. Davis et al.

    The presentation and outcome of heart failure in patients with rheumatoid arthritis differs from that in the general population

    Arthritis Rheum

    (2008)
  • B. Zoller et al.

    Risk of subsequent ischemic and hemorrhagic stroke in patients hospitalized for immune-mediated diseases: a nationwide follow-up study from Sweden

    BMC Neurol

    (2012)
  • A.K. Bacani et al.

    Noncardiac vascular disease in rheumatoid arthritis: increase in venous thromboembolic events?

    Arthritis Rheum

    (2012)
  • K.P. Liang et al.

    Incidence of noncardiac vascular disease in rheumatoid arthritis and relationship to extraarticular disease manifestations

    Arthritis Rheum

    (2006)
  • J.K. Alkaabi et al.

    Rheumatoid arthritis and macrovascular disease

    Rheumatology

    (2003)
  • M.E. Holmqvist et al.

    Risk of venous thromboembolism in patients with rheumatoid arthritis and association with disease duration and hospitalization

    JAMA

    (2012)
  • E. Myasoedova et al.

    Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease

    Ann Rheum Dis

    (2010)
  • T.E. Toms et al.

    Dyslipidaemia in rheumatoid arthritis: the role of inflammation, drugs, lifestyle and genetic factors

    Curr Vasc Pharmacol

    (2010)
  • J. Watanabe et al.

    Proteomic profiling following immunoaffinity capture of high-density lipoprotein: association of acute-phase proteins and complement factors with proinflammatory high-density lipoprotein in rheumatoid arthritis

    Arthritis Rheum

    (2012)
  • H.M. Maradit Kremers et al.

    Prognostic importance of low body mass index in relation to cardiovascular mortality in rheumatoid arthritis

    Arthritis Rheum

    (2004)
  • J.T. Giles et al.

    Abdominal adiposity in rheumatoid arthritis: association with cardiometabolic risk factors and disease characteristics

    Arthritis Rheum

    (2010)
  • V.F. Panoulas et al.

    Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis

    Rheumatology (Oxford)

    (2007)
  • H. Maradit-Kremers et al.

    Cardiovascular death in rheumatoid arthritis: a population-based study

    Arthritis Rheum

    (2005)
  • K.P. Liang et al.

    Autoantibodies and the risk of cardiovascular events

    J Rheumatol

    (2009)
  • T. Sokka et al.

    Poor physical fitness and performance as predictors of mortality in normal populations and patients with rheumatic and other diseases

    Clin Exp Rheumatol

    (2008)
  • J.K. Cooney et al.

    Benefits of exercise in rheumatoid arthritis

    J Aging Res

    (2011)
  • A.B. Lemmey et al.

    Effects of high-intensity resistance training in patients with rheumatoid arthritis: a randomized controlled trial

    Arthritis Rheum

    (2009)
  • Z. de Jong et al.

    Is a long-term high-intensity exercise program effective and safe in patients with rheumatoid arthritis? Results of a randomized controlled trial

    Arthritis Rheum

    (2003)
  • C.H. van den Ende et al.

    Effect of intensive exercise on patients with active rheumatoid arthritis: a randomised clinical trial

    Ann Rheum Dis

    (2000)
  • G.B. Neuberger et al.

    Predictors of exercise and effects of exercise on symptoms, function, aerobic fitness, and disease outcomes of rheumatoid arthritis

    Arthritis Rheum

    (2007)
  • L. Noreau et al.

    Effects of a modified dance-based exercise on cardiorespiratory fitness, psychological state and health status of persons with rheumatoid arthritis

    Am J Phys Med Rehabil

    (1995)
  • H.M. Maradit Kremers et al.

    Preventive medical services among patients with rheumatoid arthritis

    J Rheumatol

    (2003)
  • Cited by (0)

    Ms Crowson has research funding from Pfizer and Roche/Genentech. Dr Liao is supported by National Institutes of Health (NIH) K08 AR060257 and Katherine Swan Ginsburg Fund. Dr Davis is a site primary investigator for industry-sponsored trials with UCB Pharma and Roche. Dr Solomon is supported by NIH K24 AR 055989; receives research support from Amgen, Lilly, and Abbott; serves as an epidemiologic consultant to CORRONA; and serves in unpaid roles on 2 Pfizer sponsored trials. Dr Matteson has research funding from Pfizer and is involved in an industry-sponsored trial with Roche/Genentech. Drs Knutson and Hlatky reported that they have no relationships relevant to the contents of this manuscript to disclose. Dr Hlatky is funded by the American Heart Association. Dr Gabriel is supported by NIH R01 AR46849, receives research support from Pfizer, and serves as a consultant for Roche/Genentech.

    View full text